These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 25328947)

  • 1. Lymphocytes prognostic in breast cancer.
    Sklan A
    Lancet Oncol; 2014 Sep; 15(10):e422. PubMed ID: 25328947
    [No Abstract]   [Full Text] [Related]  

  • 2. Adjuvant capecitabine for HER2-negative breast cancer.
    Burki TK
    Lancet Oncol; 2017 Jul; 18(7):e375. PubMed ID: 28602775
    [No Abstract]   [Full Text] [Related]  

  • 3. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
    Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
    Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant chemotherapy for node-positive breast cancer patients: which is the reference today?
    Fumoleau P; Bonneterre J; Luporsi E
    J Clin Oncol; 2003 Mar; 21(6):1190-1; author reply 1191-2. PubMed ID: 12637489
    [No Abstract]   [Full Text] [Related]  

  • 5. Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer.
    Perez EA; Ballman KV; Tenner KS; Thompson EA; Badve SS; Bailey H; Baehner FL
    JAMA Oncol; 2016 Jan; 2(1):56-64. PubMed ID: 26469139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [San Antonio Breast Cancer Symposium 2003. New therapeutic prospects in the treatment of early-stage breast cancer].
    Montemurro F
    Tumori; 2004; 90(1):suppl 1-16. PubMed ID: 15143995
    [No Abstract]   [Full Text] [Related]  

  • 7. Can early response assessment guide neoadjuvant chemotherapy in early-stage breast cancer?
    Esteva FJ; Hortobagyi GN
    J Natl Cancer Inst; 2008 Apr; 100(8):521-3. PubMed ID: 18398093
    [No Abstract]   [Full Text] [Related]  

  • 8. Dose density in breast cancer: a simple message?
    Lin NU; Gelman R; Winer EP
    J Natl Cancer Inst; 2005 Dec; 97(23):1712-4. PubMed ID: 16333021
    [No Abstract]   [Full Text] [Related]  

  • 9. Adjuvant pertuzumab improves early breast cancer outcomes.
    Das M
    Lancet Oncol; 2017 Jul; 18(7):e378. PubMed ID: 28625555
    [No Abstract]   [Full Text] [Related]  

  • 10. Tumors with high-density tumor infiltrating lymphocytes constitute a favorable entity in breast cancer: a pooled analysis of four prospective adjuvant trials.
    Kotoula V; Chatzopoulos K; Lakis S; Alexopoulou Z; Timotheadou E; Zagouri F; Pentheroudakis G; Gogas H; Galani E; Efstratiou I; Zaramboukas T; Koutras A; Aravantinos G; Samantas E; Psyrri A; Kourea H; Bobos M; Papakostas P; Kosmidis P; Pectasides D; Fountzilas G
    Oncotarget; 2016 Jan; 7(4):5074-87. PubMed ID: 26506242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose chemotherapy for breast cancer: any use for it?
    Gianni L
    Ann Oncol; 2002 May; 13(5):650-2. PubMed ID: 12075732
    [No Abstract]   [Full Text] [Related]  

  • 12. Biomarkers Predicting Pathologic Complete Response to Neoadjuvant Chemotherapy in Breast Cancer.
    Li XB; Krishnamurti U; Bhattarai S; Klimov S; Reid MD; O'Regan R; Aneja R
    Am J Clin Pathol; 2016 Jun; 145(6):871-8. PubMed ID: 27298399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2- breast cancer: results from two prospective trials.
    Dieci MV; Frassoldati A; Generali D; Bisagni G; Piacentini F; Cavanna L; Cagossi K; Puglisi F; Michelotti A; Berardi R; Banna G; Goubar A; Ficarra G; Griguolo G; Conte P; Guarneri V
    Breast Cancer Res Treat; 2017 Jun; 163(2):295-302. PubMed ID: 28289852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Value of Tumor-Infiltrating Lymphocyte Density Assessed Using a Standardized Method Based on Molecular Subtypes and Adjuvant Chemotherapy in Invasive Breast Cancer.
    Jang N; Kwon HJ; Park MH; Kang SH; Bae YK
    Ann Surg Oncol; 2018 Apr; 25(4):937-946. PubMed ID: 29330719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting.
    Carbognin L; Pilotto S; Nortilli R; Brunelli M; Nottegar A; Sperduti I; Giannarelli D; Bria E; Tortora G
    Oncologist; 2016 Mar; 21(3):283-91. PubMed ID: 26865589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-dense treatment prolongs disease-free survival of women with node positive breast cancer.
    Dang C; Seidman AD
    Cancer Treat Rev; 2003 Oct; 29(5):453-6. PubMed ID: 12972365
    [No Abstract]   [Full Text] [Related]  

  • 17. BCIRG 001 molecular analysis: prognostic factors in node-positive breast cancer patients receiving adjuvant chemotherapy.
    Dumontet C; Krajewska M; Treilleux I; Mackey JR; Martin M; Rupin M; Lafanechère L; Reed JC
    Clin Cancer Res; 2010 Aug; 16(15):3988-97. PubMed ID: 20576719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant use of taxanes for patients with breast cancer: we see the tip of the iceberg.
    Hudis C
    Clin Breast Cancer; 2002 Dec; 3(5):326-32. PubMed ID: 12533262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials.
    Solinas C; Ceppi M; Lambertini M; Scartozzi M; Buisseret L; Garaud S; Fumagalli D; de Azambuja E; Salgado R; Sotiriou C; Willard-Gallo K; Ignatiadis M
    Cancer Treat Rev; 2017 Jun; 57():8-15. PubMed ID: 28525810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New directions in hormone therapy for metastatic breast cancer.
    Namer M
    Ann Oncol; 2002; 13 Suppl 4():69-72. PubMed ID: 12401669
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.